Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ADMA

ADMA - ADMA Biologics Inc Stock Price, Fair Value and News

$16.33-0.25 (-1.51%)
Market Closed

84/100

ADMA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

84/100

ADMA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$25.09

Target 3M

$18.69

Target 6M

$20.88

ADMA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADMA Price Action

Last 7 days

-5.9%

Last 30 days

-14.5%

Last 90 days

6.9%

Trailing 12 Months

1.0%

ADMA RSI Chart

ADMA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADMA Valuation

Market Cap

3.9B

Price/Earnings (Trailing)

18.56

Price/Sales (Trailing)

7.96

EV/EBITDA

23.36

Price/Free Cashflow

95.43

ADMA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$25.09

Target 3M

$18.69

Target 6M

$20.88

ADMA Fundamentals

ADMA Revenue

Revenue (TTM)

488.6M

Rev. Growth (Yr)

12%

Rev. Growth (Qtr)

10.03%

ADMA Earnings

Earnings (TTM)

209.4M

Earnings Growth (Yr)

1.45%

Earnings Growth (Qtr)

6.46%

ADMA Profitability

Operating Margin

54.71%

EBT Margin

31.88%

Return on Equity

48.57%

Return on Assets

36.83%

Free Cashflow Yield

1.05%

ADMA Investor Care

Shares Dilution (1Y)

0.68%

Diluted EPS (TTM)

0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025459.4M474.2M488.6M0
2024283.2M330.2M382.8M426.5M
2023181.9M208.1M234.3M258.2M
202294.0M110.1M130.5M154.1M
202148.1M58.1M68.5M80.9M
202036.0M37.2M40.3M42.2M
201916.5M18.4M21.4M29.3M
201824.2M25.4M24.9M17.0M
201711.2M12.3M14.1M22.8M
20167.8M8.8M9.8M10.7M
20155.9M5.7M6.2M7.2M
20143.8M4.6M4.9M5.9M
20131.9M2.4M3.2M3.1M
20121.7M1.5M1.3M1.1M
20110001.9M
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About ADMA Biologics Inc

ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
 CEO
 WEBSITEadmabiologics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES617

ADMA Biologics Inc Frequently Asked Questions

ADMA is the stock ticker symbol of ADMA Biologics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ADMA Biologics Inc is 3.89 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ADMA's fair value in chart for subscribers.

The fair value guage provides a quick view whether ADMA is over valued or under valued. Whether ADMA Biologics Inc is cheap or expensive depends on the assumptions which impact ADMA Biologics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADMA.

As of Wed Jan 28 2026, ADMA's PE ratio (Price to Earnings) is 18.56 and Price to Sales (PS) ratio is 7.96. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADMA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ADMA Biologics Inc has provided 0.105 (multiply by 100 for percentage) rate of return.